Position of the Transparency Council – Truqap (capivasertib)
At its meeting on 5 May 2025, the Transparency Council adopted position No. 53/202 on the assessment of the medicinal product Truqap (capivasertib) under the B.9.FM drug program. “Treatment of patients with breast cancer (ICD-10: C50)”.